A Double-Masked, Placebo-Controlled Study of Fluoxetine for Hypochondriasis
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
This study assessed the efficacy, durability, and tolerability of fluoxetine for hypochondriasis, a disorder for which controlled pharmacological trials are scarce. Fifty-seven patients with hypochondriasis were enrolled: 12 discontinued during the placebo run-in, and 45 were randomized to either fluoxetine or placebo for 12 weeks (acute treatment). Responder status was defined as a Clinical Global Impression rating for hypochondriasis of much or very much improved. Secondary outcome measures included severity of hypochondriasis, somatization, anxiety, and depression. Responders to acute treatment entered a 12-week maintenance phase to week 24. Sustained responders at week 24 entered a 12-week double-masked discontinuation phase. Primary analysis used the intent-to-treat sample. More patients responded with improvement in hypochondriasis when given fluoxetine compared with placebo, starting at week 8 (50.0% vs 19.0%, P = 0.03) and continuing to week 12 (62.5% vs 33.3%, P = 0.05). Mean dose at week 12 dose was 51.4 mg (SD, +/-23 mg). The acute treatment response was maintained to week 24 with more responders in the fluoxetine compared with the placebo group (54.2% vs 23.8%, P = 0.04). Significant improvement was not noted on the continuous secondary outcomes measures of hypochondriasis, with the exception of the Clinical Global Impression hypochondriasis severity scale at week 24. Likelihood of response was not associated with severity of psychiatric comorbidity. Durability of response after controlled drug discontinuation could not be reasonably assessed, given the small sample size of patients who entered the discontinuation phase (n = 10). Fluoxetine was well tolerated, with no significant differences in discontinuation due to side effects between treatment groups. Fluoxetine is a moderately effective and well-tolerated treatment for hypochondriasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacotherapy studies are lacking, but two studies into treatments for Hypochondriasis support the use of Fluoxetine in combination with CBT, or alone [86, 87], and another earlier study found Paroxetine yielded similar effectiveness to CBT for hypochondriasis [88].”
From Illness Anxiety Disorder: A Review of the Current Research and Future Directions (2024) · cites this paper as [87]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These studies used scales of relevance to CYB such as the Y-BOCS modified for hypochondriasis [116,117].”
From Is cyberchondria a new transdiagnostic digital compulsive syndrome? A systematic review of the evidence (2020) · cites this paper as [117]
In the citing paper
“To date, there have only been three trials of drug treatment in hypochondriasis (and none in health anxiety) (Greeven 2007; Fallon 2008; Fallon 2017).”
From Health anxiety: Detection and treatment (2018) · cites this paper as Fallon 2008
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455 · cited 1×
“Other psychopathology was assessed by the Somatic Symptom Inventory (SSI),15,16 Beck Depression Inventory (BDI),(17) the Hamilton Depression Scale (HAM-D) (24 items),(18) and the Hamilton Anxiety Scale (HAM-A).(19)”
MethodThe Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Pilowsky, I. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.494.89 · Cited by 865 · cited 2×
“Other hypochondriasis-specific assessments included the IEadministered measures (the Heightened Illness Concern [HIC] Severity Scale(11) and the Columbia Heightened Illness Concern–Obsessive-Compulsive Scale [CHIC-OCS]), a hypochondriasis-focused adaptation of the well-standardized Yale-Brown Obsessive Compulsive Scal…”
MethodCognitive Behavior Therapy for Hypochondriasis: A Randomized Controlled Trial
Barsky, A. J., & Ahern, D. K. (2004) · JAMA · doi:10.1001/jama.291.12.1464 · Cited by 307 · cited 1×
“These studies indicate that cognitive behavioral therapy can be helpful for patients with hypochondriasis.(7,8) However, there has been only 1 prior placebo-controlled pharmacotherapy study(9); this study demonstrated the short-term effectiveness of paroxetine, a selective serotonin reuptake inhibitor (SSRI), for the…”
BackgroundTwo psychological treatments for hypochondriasis: A randomised controlled trial
Clark, D. M., Salkovskis, P. M., Hackmann, A., Wells, A., Fennell, M., Ludgate, J., Ahmad, S., Richards, H. C., & Gelder, M. (1998) · British Journal of Psychiatry · doi:10.1192/bjp.173.3.218 · Cited by 270 · cited 1×
“These studies indicate that cognitive behavioral therapy can be helpful for patients with hypochondriasis.(7,8) However, there has been only 1 prior placebo-controlled pharmacotherapy study(9); this study demonstrated the short-term effectiveness of paroxetine, a selective serotonin reuptake inhibitor (SSRI), for the…”
BackgroundLin, E. H. B., Katon, W., Von Korff, M., Bush, T., Lipscomb, P., Russo, J., & Wagner, E. (1991) · Journal of General Internal Medicine · doi:10.1007/bf02598969 · Cited by 208 · cited 1×
“These patients respond poorly to standard medical management, often receive unnecessary tests or medical care, and are perceived by physicians as reluctant to accept a psychotherapy referral.(5,6) Despite its prevalence and adverse personal and public health impact, hypochondriasis has only recently been the subject o…”
BackgroundGreeven, A., van Balkom, A. J. L. M., Visser, S., Merkelbach, J. W., van Rood, Y. R., van Dyck, R., Van der Does, A. J. W., Zitman, F. G., & Spinhoven, P. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.1.91 · Cited by 183
The prevalence of hypochondriasis in medical outpatients
BARSKY, A. J., Wyshak, G., Klerman, G. L., & Latham, K. S. (1990) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00794988 · Cited by 166
Weinstein, M. C., Berwick, D. M., Goldman, P. A., Murphy, J. M., & Barsky, A. J. (1989) · Medical Care · doi:10.1097/00005650-198906000-00003 · Cited by 157
Research works printed but not linked: 1
- 11. Fallon BA. Pharmacologic strategies for hypochondriasis. In: Starcevic V, Lipsitt DR, eds. Hypochondriasis: Modern Perspectives on an Ancient Malady . New York, NY: Oxford University Press; 2001:329-351.
Cited by
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…is not normally acceptable to patients, as those with marked health anxiety are typically very sensitive to adverse effects of medication: but fluoxetine showed some benefit over placebo, though this was not pronounced and occurred late in treatment (8–12 weeks [I (PCT)] (Fallon et al., 2008).”
BackgroundShould an obsessive-compulsive spectrum grouping of disorders be included in DSM-V?
Phillips, K. A., Stein, D. J., Rauch, S. L., Hollander, E., Fallon, B. A., Barsky, A., Fineberg, N., Mataix-Cols, D., Ferrão, Y. A., Saxena, S., et al. (2010) · Depression and Anxiety · doi:10.1002/da.20705 · Cited by 347
“Although no study has directly compared the relative responsiveness to treatment of patients with HYP versus SD, there are controlled studies using either CBT or SSRI therapy among patients with HYP that suggest that improvement is substantially greater on measures of health anxiety than on measures of somatization.([…”
BackgroundResultSelf-citationVismara, M., Caricasole, V., Starcevic, V., Cinosi, E., Dell'Osso, B., Martinotti, G., & Fineberg, N. A. (2020) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2020.152167 · Cited by 224
Illness Anxiety Disorder: Psychopathology, Epidemiology, Clinical Characteristics, and Treatment.
Scarella, T. M., Boland, R. J., & Barsky, A. J. (2019) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000691 · Cited by 102
Recent Advances in the Understanding and Treatment of Health Anxiety.
Tyrer, P. (2018) · Current Psychiatry Reports · doi:10.1007/s11920-018-0912-0 · Cited by 102
The Relationship of Hypochondriasis to Anxiety, Depressive, and Somatoform Disorders
Scarella, T. M., Laferton, J. A. C., Ahern, D. K., Fallon, B. A., & Barsky, A. (2016) · Psychosomatics · doi:10.1016/j.psym.2015.10.006 · Cited by 93
“Evidence that selective serotonin reuptake inhibitors have therapeutic benefit in HC, and that relatively high doses are required for efficacy, may support categorization as an anxiety disorder rather than a disorder of somatization (9,10).”
BackgroundSelf-citationA randomized controlled trial of medication and cognitive-behavioral therapy for hypochondriasis
Fallon, B. A., Ahern, D. K., Pavlicova, M., Slavov, I., Skritskya, N., & Barsky, A. J. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16020189 · Cited by 65
“Two randomized placebocontrolled trials (17, 18) demonstrated the benefit of a selective serotonin reuptake inhibitor (SSRI).”
Self-citationPsychopharmacotherapy of somatic symptoms disorders
Somashekar, B., Jainer, A. K., & Wuntakal, B. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2012.729758 · Cited by 65
“…in hypochondriasis and body dysmorphic disorder (BDD) Several studies have reported positive results with antidepressants in treatment of hypochondriasis (Fallon et al., 1993, 1996, 2008; Greeven et al., 2007; Magarinos et al., 2002; Pilowsky, 1968; Stone, 1993; Wesner & Noyes, 1991).”
ResultCyberchondria: conceptual relation with health anxiety, assessment, management and prevention
Menon, V., Kar, S. K., Tripathi, A., Nebhinani, N., & Varadharajan, N. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102225 · Cited by 65
Greeven, A., van Balkom, A. J. L. M., van der Leeden, R., Merkelbach, J. W., van den Heuvel, O. A., & Spinhoven, P. (2009) · Journal of Behavior Therapy and Experimental Psychiatry · doi:10.1016/j.jbtep.2009.06.005 · Cited by 55
Illness Anxiety Disorder: A Review of the Current Research and Future Directions
Kikas, K., Werner-Seidler, A., Upton, E., & Newby, J. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01507-2 · Cited by 51
“Pharmacotherapy studies are lacking, but two studies into treatments for Hypochondri-asis support the use of Fluoxetine in combination with CBT, or alone [86, 87], and another earlier study found Paroxetine yielded similar effectiveness to CBT for hypochondriasis [88].”
ResultCyberchondria: a Growing Concern During the COVID-19 Pandemic and a Possible Addictive Disorder?
Mestre‐Bach, G., & Potenza, M. N. (2023) · Current Addiction Reports · doi:10.1007/s40429-022-00462-3 · Cited by 53
Generalized Anxiety Disorder and Pain
Bandelow, B. (2015) · Modern trends in psychiatry · doi:10.1159/000435939 · Cited by 48
New challenges in facing cyberchondria during the coronavirus disease pandemic
Vismara, M. E. M., Varinelli, A., Pellegrini, L., Enara, A., & Fineberg, N. A. (2022) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2022.101156 · Cited by 41
“There have been three positive RCTs [57–59] showing SSRI reduces symptoms of hypochondriasis with some preliminary evidence of an advantage for combining SSRI with CBT and for higher SSRI dosages [59].”
Health anxiety: Detection and treatment
Tyrer, P., & Tyrer, H. (2018) · BJPsych Advances · doi:10.1192/bja.2017.5 · Cited by 33
Personality Disorders in Hypochondriasis: Prevalence and Comparison with Two Anxiety Disorders
Fallon, B. A., Harper, K. M., Landa, A., Pavlicová, M., Schneier, F. R., Carson, A., Harding, K. J. K., Keegan, K. A., Schwartz, T., & Liebowitz, M. R. (2012) · Psychosomatics · doi:10.1016/j.psym.2012.02.002 · Cited by 36
Self-citationHiggins‐Chen, A., Abdallah, S. B., Dwyer, J. B., Kaye, A. P., Angarita, G. A., & Bloch, M. H. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00150 · Cited by 34
“Randomized controlled trials support efficacy of SSRIs in treating IAD though they are less effective than psychotherapy (18, 19).”
BackgroundFineberg, N. A., Pellegrini, L., Clarke, A., Perera, U., Drummond, L. M., Albert, U., & Laws, K. R. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152334 · Cited by 28
Long-Term Follow-Up of Hypochondriasis After Selective Serotonin Reuptake Inhibitor Treatment
Schweitzer, P. J., Zafar, U., Pavlicová, M., & Fallon, B. A. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31821896c3 · Cited by 27
“Further details are available in previous publications.(5,6)”
Self-citationSkritskaya, N. A., Carson-Wong, A. R., Moeller, J. R., Shen, S., Barsky, A. J., & Fallon, B. A. (2012) · Depression and Anxiety · doi:10.1002/da.21949 · Cited by 21
“Our prior research[7] used an unpublished hypochondriasis-modified version of the Y-BOCS (labeled CHIC-OCS—“Columbia Heightened Illness Concern-Obsessive Compulsive Scale”).”
MethodSelf-citationStarčević, V. (2014) · Current Psychiatry Reviews · doi:10.2174/1573400509666131119011010 · Cited by 24
“With regard to pharmacological treatment, one study has found that response to fluoxetine in hypochondriacal patients may be maintained after the medication is discontinued [50], whereas discontinuation of pharmacotherapy in OCD patients is more likely to lead to a quick deterioration [51].”
BackgroundHypochondriacal Symptoms Associated With a Less Therapeutic Physician-Patient Relationship
Noyes, R., Longley, S. L., Langbehn, D. R., Stuart, S. P., & Kukoyi, O. A. (2010) · Psychiatry · doi:10.1521/psyc.2010.73.1.57 · Cited by 16
Greeven, A., van Balkom, A. J. L. M., & Spinhoven, P. (2014) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000133 · Cited by 13
Cyberchondria, cyberhoarding, and other compulsive online disorders
Vismara, M. E. M., Caricasole, V., Varinelli, A., & Fineberg, N. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822201-0.00001-0 · Cited by 15
Health Anxiety: A Cognitive-Behavioral Framework
Rutter, L., Nota, J. A., Yusufov, M., & Björgvinsson, T. (2018) · Somatoform and Other Psychosomatic Disorders · doi:10.1007/978-3-319-89360-0_11 · Cited by 8
Somatoforme Störungen – somatoforme Belastungsstörung und verwandte Störungen
Kapfhammer, H. (2017) · Springer eBooks · doi:10.1007/978-3-662-49295-6_74 · Cited by 14
Hypochondriasis and Somatization Disorder: New Perspectives
Lipsitt, D. R. (2014) · Springer eBooks · doi:10.1007/978-3-319-11005-9_23 · Cited by 11
Psychopharmakotherapeutische Ansätze bei somatoformen Störungen und funktionellen Körpersyndromen
Kapfhammer, H. (2012) · Der Nervenarzt · doi:10.1007/s00115-011-3446-9 · Cited by 9
Effect of Aripiprazole Augmentation for Treatment-Resistant Somatoform Disorder: A Case Series
Nagoshi, Y., Tominaga, T., & Fukui, K. (2014) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000063 · Cited by 9
Identification, assessment and treatment of individual patients
Creed, F. H., Feltz-Cornelis, C. M. V. D., Guthrie, E., Henningsen, P., Rief, W., Schröder, A., & White, P. D. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511977862.009 · Cited by 10
Spectre du trouble obsessionnel-compulsif revisité à travers un bipôle impulsion-compulsion
Doumy, O., & Aouizerate, B. (2013) · La Presse Médicale · doi:10.1016/j.lpm.2013.03.011 · Cited by 8
Validity of Current Treatment Protocols to Overcome Hypochondriasis
Khare, S., & Srivastava, M. N. (2017) · JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH · doi:10.7860/jcdr/2017/22509.9262 · Cited by 7
Blonanserin Augmentation for Treatment-Resistant Somatic Symptom Disorder: A Case Series
Nagoshi, Y., Tominaga, T., & Fukui, K. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000134 · Cited by 7
“A lthough controversial, illness anxiety disorder (previously termed hypochondriasis) is often included in the obsessive– compulsive spectrum disorders, and effective treatment with selective serotonin reuptake inhibitors (SSRIs) has been demonstrated.(4,5) Because somatic symptom disorder (previously termed somatofor…”
BackgroundPrevalence and associated factors of health anxiety in patients with temporomandibular disorders
Sun, W., Fang, S., Wang, Y., Zheng, Y., Zhou, X., Yi, Y., Xiong, X., & Wang, J. (2024) · Oral Diseases · doi:10.1111/odi.15037 · Cited by 6
Yutzy, S. H. (2015) · Wiley eBooks · doi:10.1002/9781118753378.ch62 · Cited by 3
Prithviraj, M., Mohanraj, P. S., Patel, T. K., & Das, A. (2023) · Cureus · doi:10.7759/cureus.45286 · Cited by 3
Salehi, C., Kershaw, K. A., Storer, B., Newby, J. M., & Murphy, M. J. (2024) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2024.100209 · Cited by 3
Harding, K. J. K., Skritskaya, N. A., Doherty, E. R., & Fallon, B. A. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.012 · Cited by 3
Self-citationKapfhammer, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-03637-8_61 · Cited by 3
Thibodeau, M. A., Asmundson, G. J. G., & Taylor, S. J. (2013) · Wiley eBooks · doi:10.1002/9781118330043.ch6 · Cited by 3
Starčević, V. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.025 · Cited by 2
Bleichhardt, G. M., & Rief, W. (2014) · Wiley eBooks · doi:10.1002/9781118775349.ch26 · Cited by 3
Psychopharmakotherapie somatoformer Störungen
Eser-Valeri, D. (2014) · Die Psychiatrie · doi:10.1055/s-0038-1670764 · Cited by 2
“nach 12 Wochen 51,4 + 23 mg) eine im Vergleich zu Placebo signifikante Besserung im klinischen Gesamteindruck (CGI) verzeichnet werden konnte (10).”
BackgroundCrawford, J. D., Tran, P., Shaw, J. S., & Shaw, R. J. (2020) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-020-00209-9 · Cited by 2
Scarella, T. M. (2019) · Springer eBooks · doi:10.1007/978-3-030-04245-5_6 · Cited by 3
Somatoforme Störungen – somatoforme Belastungsstörung und verwandte Störungen
Kapfhammer, H. (2016) · Springer eBooks · doi:10.1007/978-3-642-45028-0_74-1 · Cited by 2
Somatoforme Störungen und Somatisierungssyndrome
Kapfhammer, H. (2011) · Springer eBooks · doi:10.1007/978-3-642-19844-1_81 · Cited by 1
Challenges in diagnosing pathological anxiety
Simpson, H. B., Neria, Y., Lewis‐Fernández, R., & Schneier, F. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511777578.009 · Cited by 1
Self-citationHypochondrie und Gesundheitssorgen
Bleichhardt, G. M., & Rief, W. (2011) · Springer eBooks · doi:10.1007/978-3-642-16197-1_105
New Insights on the Treatment of Hypochondriasis
Phillips, K. A. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17050515
Soucy, J. N. (2016) · oURspace (University of Regina) · doi:10.82465/5180
Illness Anxiety Disorder, Somatic Symptom Disorder, and Body Dysmorphic Disorder
Fallon, B. A., & Harding, K. J. K. (2013) · Springer eBooks · doi:10.1007/978-3-642-27772-6_379-2
Self-citation身体症状症および関連症群 (身体表現性障害) の薬物療法はどこまで可能になったのか
名越, 泰. (2019) · 心身医学 · doi:10.15064/jjpm.59.6_554
Current awareness in human psychopharmacology
(2009) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.974
Illness Anxiety Disorder, Somatic Symptom Disorder, and Body Dysmorphic Disorder
Fallon, B. A., & Harding, K. J. K. (2015) · Springer eBooks · doi:10.1007/978-3-642-36172-2_379
“In 2008, Fallon et al. (2008) conducted a placebo-controlled study of fluoxetine for DSM-IV hypochondriasis among 45 randomized patients.”
Self-citationHypochondrie und Gesundheitssorgen
Bleichhardt, G. M., & Rief, W. (2015) · Springer eBooks · doi:10.1007/978-3-642-55210-6_105 · Cited by 1
(2012) · Elsevier eBooks · doi:10.1016/b978-0-323-08373-7.00017-0
Somatoform and Body Dysmorphic Disorders
Fallon, B. A., & Harding, K. J. K. (2010) · Springer eBooks · doi:10.1007/978-3-540-68706-1_379
Self-citationLooper, K. J., & Kirmayer, L. J. (2013) · Oxford University Press eBooks · doi:10.1093/obo/9780199828340-0106
General principles of management of somatization
Orsolini, L., Cicolini, A., Salvi, V., & Volpe, U. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780192858290.003.0019
González, I., Melgarejo, O. J., & Torales, J. C. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780192858290.003.0012
„Höfuðverkur eða heilaæxli?“ Fræðileg samantekt um heilsukvíða
1991, G. G., & 1991, M. Ó. M. (2016) · Skemman
Improving the diagnosis of Illness Anxiety Disorder
Maric, K. (2026) · UNSWorks (University of New South Wales, Sydney, Australia) · doi:10.26190/unsworks/32259
Skirke, M., & Schnell, T. (2026) · Essentials · doi:10.1007/978-3-662-72769-0_5
Skirke, M., & Schnell, T. (2026) · Essentials · doi:10.1007/978-3-662-72769-0_3
Metadata
- Authors
- Fallon, B. A., Petkova, E., Skritskaya, N., Sanchez-Lacay, A., Schneier, F., Vermes, D., Cheng, J., & Liebowitz, M. R.
- Affiliations
- New York State Psychiatric Institute (US)
- Corresponding author
- Fallon, Brian A.
- Skritskaya, Natalia
- Schneier, Franklin
- Vermes, Donna
- Liebowitz, Michael R.
- ORCID
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2008-12
- Volume
- 28
- Issue
- 6
- Pages
- 638-645
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2026930104
- Cited by
- 63
- References
- 20
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 3 · 2015: 5 · 2014: 7 · 2013: 5 · 2012: 4
- FWCI
- 2.80
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- National Institute of Mental Health (R29MH049409, R29 MH49409)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Psychosomatic Disorders and Their Treatments
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Keywords
- fluoxetine, health anxiety, somatic symptom disorder, SSRI antidepressants, treatment efficacy, maintenance therapy, drug discontinuation, somatization, anxiety, depression, psychiatric comorbidity, tolerability
- MeSH terms
- Adult, Aged, Connecticut, Dose-Response Relationship, Drug, Double-Blind Method, Female, Fluoxetine, Humans, Hypochondriasis, Male, Middle Aged, New York, Patient Dropouts, Psychiatric Status Rating Scales, Severity of Illness Index, Time Factors, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.